Julein Taieb: Real world evidence showing 50 MSI-H BRAF V600E mutant treated with immunotherapy

Julein Taieb, Professor, Paris Descartes University, shared a post on LinkedIn:

“BRAFmutant, MSI, colorectal cancer can be efficiently treated with encorafenib and cetuximab following a first line of treatment with immunotherapy. Evidence was lacking on this topic.

With a cohort involving many experts centers around the world, we have generated real world evidence showing that in 50 MSI-H BRAF V600E mutant treated with immunotherapy, the standard of care second line treatment: encorafenib + cetuximab was as efficient as in MSS BRAF V600E mutant CRC.

Median PFS was 5.13 (versus 4.50 months in MSS) and median OS was 10.75 (versus 9.11 months in MSS).”

BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer

Authors: Margherita Ambrosini ^, David Tougeron, Dominik Modest, Rosine Guimbaud, Scott Kopetz, Marie Decraecker, Stefano Kim, Clelia Coutzac, Geraldine Perkins, Emily Alouani, Federica Marmorino , Simon Pernot , Frank A Sinicrope , Elena Elez , Pauline Parent , Chiara Cremolini , Filippo Pietrantonio , Sara Lonardi ^, Claire Gallois, Julien Taieb

Source: Julein Taieb/LinkedIn